Foresite Capital Management V, LLC holds a concentrated book of 9 stocks worth $271.0M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Eikon Therapeutics Inc and trimmed Maze Therapeutics Inc. Their largest long position is Alumis Inc at 48% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1792206/holdings"
Use Arkolith to show Foresite Capital Management V, LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Alumis Inc. COM | $129.9M | 5.90M | 47.9% | ▲+2.0% Added · +118K sh | |
| 2 | CG Oncology, Inc. COM | $68.0M | 1.00M | 25.1% | —Held | |
| 3 | Disc Medicine, Inc. COM | $23.9M | 374.1K | 8.8% | ▲+25% Added · +75K sh | |
| 4 | Hims & Hers Health, Inc. COM CL A | $15.3M | 738.2K | 5.7% | ▲+170% Added · +465K sh | |
| 5 | Eikon Therapeutics, Inc. COM | $14.0M | 1.32M | 5.1% | ▲New New position | |
| 6 | Lyell Immunopharma, Inc. COM | $9.6M | 477.1K | 3.5% | —Held | |
| 7 | Pharvaris N.V. COM | $5.5M | 194.1K | 2.0% | ▲New New position | |
| 8 | Nurix Therapeutics, Inc. COM | $4.1M | 265.0K | 1.5% | ▲New New position | |
| 9 | Maze Therapeutics, Inc. COM | $773K | 25.9K | 0.3% | ▼−70% Reduced · −60K sh |
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.